• Search
  • Advanced Search

Review

February 13, 2023


Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, et al.
Clin Mol Hepatol. 2023;29(3):593-604.

Recently, treatments for unresectable hepatocellular carcinoma (HCC) have undergone remarkable development. Various systemic chemotherapy drugs have been approved and are recommended by clinical guidelines worldwide. Although systemic treatments are effective...

Review

February 15, 2023


Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection
Chih-Lin Lin, Jia-Horng Kao
Clin Mol Hepatol. 2023;29(3):605-622.

Hepatitis B virus (HBV) is responsible for more than 50% of hepatocellular carcinoma (HCC) in HBV hyperendemic areas, such as the Asia-Pacific region. Several hepatitis B viral factors are involved...

Review

February 20, 2023


Acute hepatitis C virus infection: clinical update and remaining challenges
Chen-Hua Liu, Jia-Horng Kao
Clin Mol Hepatol. 2023;29(3):623-642.

Acute hepatitis C virus (HCV) infection is a global health concern with substantial geographical variation in the incidence rate. People who have received unsafe medical procedures, used injection drugs, and...

Review

March 6, 2023


A decade of liver organoids: Advances in disease modeling
Yue Liu, Jian-Ying Sheng, Chun-Fang Yang, et al.
Clin Mol Hepatol. 2023;29(3):643-669.

Liver organoids are three-dimensional cellular tissue models in which cells interact to form unique structures in culture. During the past 10 years, liver organoids with various cellular compositions, structural features,...

Review

March 20, 2023


Acute-on-chronic liver failure: Terminology, mechanisms and management
Vinay Kumar BR, Shiv Kumar Sarin
Clin Mol Hepatol. 2023;29(3):670-689.

Acute-on-chronic liver failure is an acute deterioration of liver function manifesting as jaundice and coagulopathy with the development of ascites, with a high probability of extrahepatic organ involvement and high...

Original Article

March 9, 2023


Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis
Min Jeong Park, Hayeon Kim, Myeong Gyu Kim, et al.
Clin Mol Hepatol. 2023;29(3):693-704.

Background/Aims: Previous studies have revealed that glucagon-like peptide-1 receptor agonist (GLP-1RA) and thiazolidinedione (TZD) can improve nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). However, comprehensive research comparing the...

Original Article

May 8, 2023


Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis
Yu Jun Wong, Vy H. Nguyen, Hwai-I Yang, et al.
Clin Mol Hepatol. 2023;29(3):705-720.

Background/Aims: Chronic hepatitis B (CHB) and fatty liver (FL) often co-exist, but natural history data of this dual condition (CHB-FL) are sparse. Via a systematic review, conventional meta-analysis (MA) and...

Original Article

March 22, 2023


Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng, et al.
Clin Mol Hepatol. 2023;29(3):721-732.

Background/Aims: Patients with cirrhosis and hepatocellular carcinoma (HCC) require extensive and personalized care to improve outcomes. ChatGPT (Generative Pre-trained Transformer), a large language model, holds the potential to provide professional...

Original Article

May 8, 2023


Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging
Yoon Jung Hwang, Jae Seok Bae, Youngeun Lee, et al.
Clin Mol Hepatol. 2023;29(3):733-746.

Background/Aims: The microvascular invasion (MVI) of hepatocellular carcinoma (HCC) involves a wide histological spectrum, and it is unclear whether the degree of MVI correlates with patient prognosis or imaging findings....

Original Article

May 10, 2023


Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients
Xiaoning Wu, Xiaoqian Xu, Jialing Zhou, et al.
Clin Mol Hepatol. 2023;29(3):747-762.

Background/Aims: Existing hepatocellular carcinoma (HCC) prediction models are derived mainly from pretreatment or early on-treatment parameters. We reassessed the dynamic changes in the performance of 17 HCC models in patients...

Original Article

May 30, 2023


Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis
Moon Haeng Hur, Yuri Cho, Do Young Kim, et al.
Clin Mol Hepatol. 2023;29(3):763-778.

Background/Aims: Transarterial radioembolization (TARE) has shown promising results in treating advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). However, whether TARE can provide superior or comparable outcomes to...

Original Article

May 15, 2023


Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study
Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, et al.
Clin Mol Hepatol. 2023;29(3):779-793.

Background/Aims: To eliminate hepatitis B virus (HBV) and hepatitis C virus (HCV) according to the World Health Organization (WHO) criteria in 2021, this study investigated the national core indicators representing...

Original Article

May 17, 2023


Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma
Jeayeon Park, Sung Won Chung, Yun Bin Lee, et al.
Clin Mol Hepatol. 2023;29(3):794-809.

Background/Aims: Chronic hepatitis B (CHB) is a risk factor for non-Hodgkin lymphoma (NHL). Our recent study suggested that antiviral treatment may reduce the incidence of NHL in CHB patients. This...
Current Issue
Volume 29(3); Jul 2023
Guideline
1841
Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association
Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim
Clin Mol Hepatol. 2023;29(3):521-541.   Published online July 1, 2023
View: 1178   Download: 98
1817
KASL clinical practice guidelines for management of autoimmune hepatitis 2022
Clin Mol Hepatol. 2023;29(3):542-592.   Published online May 3, 2023
View: 1429   Download: 188
Review
1774
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi
Clin Mol Hepatol. 2023;29(3):593-604.   Published online February 13, 2023
View: 1993   Download: 225  Citations: 3
1775
Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection
Chih-Lin Lin, Jia-Horng Kao
Clin Mol Hepatol. 2023;29(3):605-622.   Published online February 15, 2023
View: 1998   Download: 226  Citations: 3
1781
Acute hepatitis C virus infection: clinical update and remaining challenges
Chen-Hua Liu, Jia-Horng Kao
Clin Mol Hepatol. 2023;29(3):623-642.   Published online February 20, 2023
View: 2060   Download: 266  Citations: 2
1788
A decade of liver organoids: Advances in disease modeling
Yue Liu, Jian-Ying Sheng, Chun-Fang Yang, Junjun Ding, Yun-Shen Chan
Clin Mol Hepatol. 2023;29(3):643-669.   Published online March 6, 2023
View: 6452   Download: 192
1807
Acute-on-chronic liver failure: Terminology, mechanisms and management
Vinay Kumar BR, Shiv Kumar Sarin
Clin Mol Hepatol. 2023;29(3):670-689.   Published online March 20, 2023
View: 2505   Download: 470  Citations: 2
Editorial
The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B
Xianhua Mao, Lung Yi Mak, Wai-Kay Seto
Clin Mol Hepatol. 2023;29(3):690-692.   Published online May 30, 2023
View: 841   Download: 61
Original Article
1790
Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis
Min Jeong Park, Hayeon Kim, Myeong Gyu Kim, Kyungim Kim
Clin Mol Hepatol. 2023;29(3):693-704.   Published online March 9, 2023
View: 1378   Download: 124
1818
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis
Yu Jun Wong, Vy H. Nguyen, Hwai-I Yang, Jie Li, Michael Huan Le, Wan-Jung Wu, Nicole Xinrong Han, Khi Yung Fong, Elizebeth Chen, Connie Wong, Fajuan Rui, Xiaoming Xu, Qi Xue, Xin Yu Hu, Wei Qiang Leow, George Boon-Bee Goh, Ramsey Cheung, Grace Wong, Vincent Wai-Sun Wong, Ming-Whei Yu, Mindie H. Nguyen
Clin Mol Hepatol. 2023;29(3):705-720.   Published online May 8, 2023
View: 1827   Download: 149  Citations: 2
1814
Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng, Peng-Sheng Ting, Hirsh Trivedi, Aarshi Vipani, Walid Ayoub, Ju Dong Yang, Omer Liran, Brennan Spiegel, Alexander Kuo
Clin Mol Hepatol. 2023;29(3):721-732.   Published online March 22, 2023
View: 8012   Download: 1,168  Citations: 24
1819
Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging
Yoon Jung Hwang, Jae Seok Bae, Youngeun Lee, Bo Yun Hur, Dong Ho Lee, Haeryoung Kim
Clin Mol Hepatol. 2023;29(3):733-746.   Published online May 8, 2023
View: 1369   Download: 117  Citation: 1
1822
Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients
Xiaoning Wu, Xiaoqian Xu, Jialing Zhou, Yameng Sun, Huiguo Ding, Wen Xie, Guofeng Chen, Anlin Ma, HongXin Piao, Bingqiong Wang, Shuyan Chen, Tongtong Meng, Xiaojuan Ou, Hwai-I Yang, Jidong Jia, Yuanyuan Kong, Hong You
Clin Mol Hepatol. 2023;29(3):747-762.   Published online May 10, 2023
View: 1109   Download: 101
1830
Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis
Moon Haeng Hur, Yuri Cho, Do Young Kim, Jae Seung Lee, Gyoung Min Kim, Hyo-Cheol Kim, Dong Hyun Sinn, Dongho Hyun, Han Ah Lee, Yeon Seok Seo, In Joon Lee, Joong-Won Park, Yoon Jun Kim
Clin Mol Hepatol. 2023;29(3):763-778.   Published online May 30, 2023
View: 1080   Download: 117
1823
Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study
Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, Sojung Han, Eun Sun Jang, Young Eun Chon, Young Chang, Kyung-Ah Kim, Do Young Kim, Hyung Joon Yim, Hye-Lin Kim, Sook-Hyang Jeong, In Hee Kim
Clin Mol Hepatol. 2023;29(3):779-793.   Published online May 15, 2023
View: 1288   Download: 99
1824
Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma
Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee
Clin Mol Hepatol. 2023;29(3):794-809.   Published online May 17, 2023
View: 1353   Download: 92
Letter to the Editor
Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
Seogsong Jeong, Yohwan Lim, Su Kyoung Lee, Hyun Wook Han
Clin Mol Hepatol. 2023;29(3):810-811.   Published online May 8, 2023
View: 789   Download: 42
Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”
Halil Haldun Emiroglu
Clin Mol Hepatol. 2023;29(3):812-812.   Published online May 8, 2023
View: 777   Download: 15
Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
Hassam Ali
Clin Mol Hepatol. 2023;29(3):813-814.   Published online May 19, 2023
View: 959   Download: 55
Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
Amnuay Kleebayoon, Viroj Wiwanitkit
Clin Mol Hepatol. 2023;29(3):815-816.   Published online May 24, 2023
View: 797   Download: 45
Correspondence
Correspondence on Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
Seul Ki Han, Soon Koo Baik, Moon Young Kim
Clin Mol Hepatol. 2023;29(3):817-819.   Published online May 17, 2023
View: 783   Download: 33
Correspondence on Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”
Joo Hyun Oh, Dong Hyun Sinn
Clin Mol Hepatol. 2023;29(3):820-820.   Published online May 19, 2023
View: 735   Download: 21
Correspondence on Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng
Clin Mol Hepatol. 2023;29(3):821-822.   Published online May 31, 2023
View: 833   Download: 55
Correspondence on Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng
Clin Mol Hepatol. 2023;29(3):823-824.   Published online May 31, 2023
View: 775   Download: 30  Citation: 1
Snapshot
1834
HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
Soon Kyu Lee, Jung Hyun Kwon
Clin Mol Hepatol. 2023;29(3):825-827.   Published online May 31, 2023
View: 852   Download: 64
Erratum
Erratum to ‘Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?’ [Clin Mol Hepatol 2023;29:367-370]
Joo Hyun Oh, Dong Hyun Sinn
Clin Mol Hepatol. 2023;29(3):828-829.   Published online April 13, 2023
View: 649   Download: 15
Erratum to ‘Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in directacting antiviral failure in South Korea’ [Clin Mol Hepatol 2023;29:496-509]
Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, Eun Sun Jang, Youn Jae Lee, Sung Bum Cho, Young Seok Kim, In Hee Kim, Byung Seok Lee, Woo Jin Chung, Sang Hoon Ahn, Seungtaek Kim, Sook Hyang Jeong
Clin Mol Hepatol. 2023;29(3):830-830.   Published online April 13, 2023
View: 721   Download: 14

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

  • PubMed Central
  • PubMed
  • Scopus
  • KoreaMed
  • KoMCI
  • ScienceCentral
  • DOAJ
  • GoogleScholar
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • Metadata
  • ORCID
  • MeSH on Demand
  • COPE
  • EMBASE
  • KOFST
  • ICMJE
  • Web of SCIENCE
ABOUT
BROWSE ARTICLES
CURRENT ISSUE
FOR CONTRIBUTORS
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 503
TOTAL : 1452381
Close layer